

Dokumentvorlage, Version vom 18.04.2013

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Ocrelizumab (OCREVUS®)

Roche Pharma AG

Modul 4A

*Erwachsene Patienten mit aktiver
schubförmiger Multipler Sklerose (RMS)*

Aktualisierte bibliografische
Literaturrecherchen und Recherchen in
Studienregistern

Stand: 26.02.2018

Inhaltsverzeichnis

	Seite
Tabellenverzeichnis.....	3
Abbildungsverzeichnis.....	4
4.2.3.2 Bibliografische Literaturrecherche.....	5
4.2.3.3 Suche in Studienregistern.....	5
4.2.3.4 Selektion relevanter Studien.....	5
4.3.1.1.1 Studien des pharmazeutischen Unternehmers.....	6
4.3.1.1.2 Studien aus der bibliografischen Literaturrecherche.....	7
4.3.1.1.3 Studien aus der Suche in Studienregistern.....	8
4.3.1.1.4 Resultierender Studienpool: RCT mit dem zu bewertenden Arzneimittel.....	8
4.7 Referenzliste.....	9
Anhang 4-A : Suchstrategien – bibliografische Literaturrecherche.....	11
Anhang 4-B : Liste der im Volltext gesichteten und ausgeschlossenen Dokumente mit Ausschlussgrund (bibliografische Literaturrecherche).....	16
Anhang 4-C : Liste der ausgeschlossenen Studien mit Ausschlussgrund (Suche in Studienregistern).....	16

Tabellenverzeichnis

	Seite
Tabelle 4-7: Liste der Studien des pharmazeutischen Unternehmers – RCT mit Ocrelizumab.....	6
Tabelle 4-8: Studien des pharmazeutischen Unternehmers, die nicht für die Nutzenbewertung herangezogen wurden – RCT mit Ocrelizumab	6
Tabelle 4-9: Relevante Studien (auch laufende Studien) aus der Suche in Studienregistern – RCT mit Ocrelizumab.....	8
Tabelle 4-10: Studienpool – RCT mit Ocrelizumab.....	8

Abbildungsverzeichnis

Seite

Abbildung 1: Flussdiagramm der bibliografischen Literaturrecherche – Suche nach randomisierten kontrollierten Studien mit Ocrelizumab..... 7

4.2.3.2 Bibliografische Literaturrecherche

Um RCT mit Ocrelizumab im Anwendungsgebiet der frühen PPMS zu identifizieren, wurde eine systematische Literaturrecherche in den Datenbanken MEDLINE und Embase, sowie in den Datenbanken der Cochrane Library durchgeführt. Die Suchstrategien wurden jeweils speziell im Hinblick auf die Syntax der einzelnen Datenbanken optimiert. Die Strategien für die Suche nach RCT in MEDLINE und Embase bestehen regulär aus je drei Blöcken: Intervention, Indikation und Studientyp. Für die Einschränkung auf den Studientyp wurde ein validierter Filter (1) verwendet, welcher an die Syntax des verwendeten Datenbankhosts ProQuest Dialog angepasst wurde. Weitere Einschränkungen (z.B. Datum, Sprache) wurden nicht vorgenommen. In den Cochrane Datenbanken wurden nur die beiden Blöcke Intervention und Indikation miteinander verknüpft, auf eine Einschränkung auf einen Studientyp wurde verzichtet. Es wurden keine weiteren Einschränkungen vorgenommen. Die Recherche in den Cochrane-Datenbanken wurde über die Suchoberfläche der Cochrane Library (advanced search) durchgeführt. Die jeweiligen Suchstrategien sind in Anhang 4-A dokumentiert.

4.2.3.3 Suche in Studienregistern

Die Recherchen für RCT bezüglich Ocrelizumab wurden den Vorgaben entsprechend in den Studienregistern clinicaltrials.gov, ICTRP Search Portal, EU ClinicalTrials Register und PharmNet.Bund durchgeführt. Zunächst wurden alle bekannten Synonyme und Schreibweisen des zu bewertenden Arzneimittels einzeln gesucht und die Trefferzahlen dokumentiert. Abschließend wurden nur die Begriffe, welche Treffer erzielten, miteinander kombiniert und die jeweiligen Ergebnisse exportiert. Alle Recherchen erfolgten über die jeweilige Basic Search. Weiteren Einschränkungen in den Datenbanken wurden nicht vorgenommen. Da die Suchoberfläche von PharmNet.Bund nicht genügend Felder bietet, um die vollständige Suchstrategie auf einmal auszuführen, wurden in diesem Fall mehrere Recherchen durchgeführt und die Ergebnisse abschließend miteinander abgeglichen, um Duplikate zu eliminieren. Aus den exportierten Ergebnissen wurden anschließend die Studien gemäß der in Abschnitt 4.2.2 gelisteten Ein- und Ausschlusskriterien selektiert. Die jeweiligen Suchstrategien sind in Anhang 4-B dokumentiert.

4.2.3.4 Selektion relevanter Studien

Die über die systematische Literaturrecherche identifizierten Publikationen wurden um Dubletten bereinigt. Die Beurteilung der Relevanz erfolgte zunächst anhand der Titel und/oder Abstracts. Treffer, die aufgrund der in Abschnitt 4.2.2 gelisteten Ein- und Ausschlusskriterien als nicht relevant eingestuft wurden, wurden ausgeschlossen. Publikationen, bei denen eine eindeutige Relevanzbeurteilung anhand der Titel/Abstracts nicht möglich war, wurden im Volltext begutachtet und die relevanten Ausschlussgründe entsprechend dokumentiert (Anhang 4-C). Der gesamte Auswahlprozess wurde jeweils von zwei Reviewern unabhängig voneinander durchgeführt, bei Diskrepanzen in der Bewertung wurde durch Diskussion ein Konsens erreicht. Bei der Suche in Studienregistern wurde jeder Registereintrag ebenfalls unabhängig von zwei Reviewern beurteilt und, soweit nötig, ein Konsens gefunden.

4.3.1.1.1 Studien des pharmazeutischen Unternehmers

Tabelle 4-7: Liste der Studien des pharmazeutischen Unternehmers – RCT mit Ocrelizumab

Studie	Zulassungsstudie (ja/nein)	Sponsor (ja/nein)	Status (abgeschlossen / abgebrochen / laufend)	Studiendauer	Therapiearme
WA21092 OPERA I	ja	ja	abgeschlossen	96 Wochen	Ocrelizumab 600 mg i.v. Interferon β 1a 44 μ g s.c.
WA21093 OPERA II	ja	ja	abgeschlossen	96 Wochen	Ocrelizumab 600 mg i.v. Interferon β 1a 44 μ g s.c.
WA21493	ja	ja	abgeschlossen	Aktiv kontrollierte Phase 24 Wochen Phase ohne aktiven Komparator 72 Wochen	Placebo Ocrelizumab 600 mg i.v. Ocrelizumab 1000 mg i.v. Avonex 30 μ g i.m.
BN29739	nein	ja	laufend	Bis zu 7 Jahren (mit Safety-Follow-up-Phasen)	Ocrelizumab + Vakzine Vakzine (Ocrelizumab optional in der Extension-Phase)

Stand der Information: 14.02.2018

Tabelle 4-8: Studien des pharmazeutischen Unternehmers, die nicht für die Nutzenbewertung herangezogen wurden – RCT mit Ocrelizumab

Studienbezeichnung	Begründung für die Nichtberücksichtigung der Studie
BN29739	A3 (andere Vergleichstherapie)
WA21493	A6 (weniger als 12 Monate)

4.3.1.1.2 Studien aus der bibliografischen Literaturrecherche




Abbildung 1: Flussdiagramm der bibliografischen Literaturrecherche – Suche nach randomisierten kontrollierten Studien mit Ocrelizumab

Die systematische bibliografische Recherche zur Identifizierung von RCT zu Ocrelizumab in der Indikation RMS wurde erneut am 14.02.2018 in allen 3 beschriebenen Datenbanken durchgeführt. Die entsprechenden Suchstrategien sind in Anhang 4-A1 dokumentiert.

Dabei wurden insgesamt 319 Treffer erzielt. Nach Ausschluss von 72 Duplikaten wurden die verbliebenen 247 Treffer einem Screeningprozess (siehe Abbildung 1) unterzogen, in dem sie gemäß der in Abschnitt 4.2.2 gelisteten Kriterien selektiert wurden. Nach Ausschluss der anhand Titel/Abstract als nicht relevant eingestuftem Dokumente wurden schließlich zwei Artikel anhand der Volltexte beurteilt und einer davon als relevant eingestuft. Dabei handelt es sich um die Publikation zu den Studien OPERA I und OPERA II (2).

4.3.1.1.3 Studien aus der Suche in Studienregistern

Tabelle 4-9: Relevante Studien (auch laufende Studien) aus der Suche in Studienregistern – RCT mit Ocrelizumab

Studie	Identifikationsorte (Name des Studienregisters und Angabe der Zitate ^a)	Studie in Liste der Studien des pharmazeuti- schen Unterneh- mers enthalten (ja/nein)	Studie durch biblio- grafische Literatur- recherche identifi- ziert (ja/nein)	Status (abgeschlossen/ abgebrochen/ laufend)
WA21092 (OPERA I)	clinicaltrials.gov (3) WHO ICTRP (4–6) EU-CTR (7) PharmNet.Bund (8)	ja	ja (2)	abgeschlossen
WA21093 (OPERA II)	clinicaltrials.gov (9) WHO ICTRP (10) EU-CTR (11) PharmNet.Bund (12)	ja	ja (2)	abgeschlossen

a: Zitat des Studienregistereintrags sowie, falls vorhanden, der im Studienregister aufgelisteten Berichte über Studiendesign und/oder Studienergebnisse.
ICTRP: International Clinical Trials Registry Platform, WHO: Weltgesundheitsorganisation, EU-CTR: EU Clinical Trials Register

Die Suche zur Identifizierung von RCTs mit dem zu bewertenden Arzneimittel aus Studienregistern wurde erneut am 14.02.2018 in den Registern Clinicaltrials.gov, ICTRP, EU-CTR und PharmNet.Bund durchgeführt. Die anschließende Selektion erfolgte gemäß der in Abschnitt 4.2.2 gelisteten Kriterien.

Die beiden in Tabelle 4-9 dargestellten relevanten Studien wurden jeweils in allen 4 Studienregistern gefunden (drei separate Einträge zu OPERA I in WHO ICTRP), woraus sich eine Trefferzahl von insgesamt 10 ergibt.

4.3.1.1.4 Resultierender Studienpool: RCT mit dem zu bewertenden Arzneimittel

Tabelle 4-10: Studienpool – RCT mit Ocrelizumab

Studie	Studienkategorie			verfügbare Quellen ^a		
	Studie zur Zu- lassung Ocrelizumab (ja/nein)	gesponserte Studie ^b (ja/nein)	Studie Dritter (ja/nein)	Studienbericht (ja/nein [Zitat])	Registereintrag ^c (ja/nein [Zitat])	Publikation (ja/nein [Zi- tat])
aktivkontrolliert, zweckmäßige Vergleichstherapie(n)						
OPERA I WA21092	ja	ja	nein	ja (13)	ja clinicaltrials.gov NCT01247324 (14)	ja (13)
OPERA II WA21093	ja	ja	nein	ja (15)	ja clinicaltrials.gov NCT01412333 (16)	ja (15)

a: Bei Angabe „ja“ sind jeweils die Zitate der Quelle(n) (z. B. Publikationen, Studienberichte, Studienregistereinträge) mit anzugeben, und zwar als Verweis auf die in Abschnitt 4.7 genannte Referenzliste. Darüber hinaus ist darauf zu achten, dass alle Quellen, auf die in dieser Tabelle verwiesen wird, auch in Abschnitt 4.6 (Liste der eingeschlossenen Studien) aufgeführt werden.
b: Studie, für die der Unternehmer Sponsor war.
c: Zitat der Studienregistereinträge sowie, falls vorhanden, der in den Studienregistern aufgelisteten Berichte über Studiendesign und/oder -ergebnisse.

4.7 Referenzliste

1. Wong SS, Wilczynski NL, Haynes RB. Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. *J Med Libr Assoc* 2006; 94(4):451–5.
2. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *N Engl J Med* 2017; 376(3):221–34.
3. ClinicalTrials.gov, Hoffmann-La Roche. A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis: NCT01247324, WA21092, 2010-020337-99; 2018. URL: <https://ClinicalTrials.gov/show/NCT01247324> [aufgerufen am: 14.02.2018].
4. WHO-ICTRP, F. Hoffmann La Roche Ltd / Genentech Inc. A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A (REBIF®) IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: PER-128-11, WA21092; 2018. URL: <http://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=128-11> [aufgerufen am: 14.02.2018].
5. WHO-ICTRP, F. Hoffmann- La Roche, Ltd /Genentech Inc. A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A (REBIF®) IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: PER-024-14, WA21092-D; 2018. URL: <http://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=024-14> [aufgerufen am: 14.02.2018].
6. WHO-ICTRP, F.Hoffmann-La Roche. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis - OPERA I: EUCTR2010-020337-99-GB, WA21092, NCT01247324; 2018. URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020337-99 [aufgerufen am: 14.02.2018].
7. EU-CTR, F.Hoffmann-La Roche. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc: 2010-020337-99, WA21092; 2018. URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020337-99 [aufgerufen am: 14.02.2018].
8. PharmNet.Bund, F. Hoffmann-La Roche. A Randomized, Double Blind, Double Dummy, Parallel Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta 1a (Rebif®) In Patients With Relapsing Multiple Sclerosis: 2010-020337-99; 2018 [aufgerufen am: 14.02.2018].
9. ClinicalTrials.gov, Hoffmann-La Roche. A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis: NCT01412333, WA21093, 2010-020315-36; 2018. URL: <https://ClinicalTrials.gov/show/NCT01412333> [aufgerufen am: 14.02.2018].
10. WHO-ICTRP, F.Hoffmann-La Roche. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis -

- OPERA II: EUCTR2010-020315-36-SK, WA21093; 2018. URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020315-36 [aufgerufen am: 14.02.2018].
11. EU-CTR, F.Hoffmann-La Roche. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc: 2010-020315-36, WA21093; 2018. URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020315-36 [aufgerufen am: 14.02.2018].
 12. PharmNet.Bund, F.Hoffmann-La Roche. A Randomized, Double Blind, Double Dummy, Parallel Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta 1a (Rebif®) In Patients With Relapsing Multiple Sclerosis: 2010-020315-36; 2018 [aufgerufen am: 14.02.2018].
 13. F. Hoffmann-La Roche Ltd / Genentech Inc. Primary Clinical Study Report – Protocol WA21092 – A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis – Report No. 1062034 – March 2016: OPERA I; 2016.
 14. ClinicalTrials.gov, Hoffmann-La Roche. A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis - ClinicalTrials.gov: OPERA I, NCT01247324, WA21092, 2010-020337-99; 2018. URL: <https://clinicaltrials.gov/ct2/show/record/NCT01247324> [aufgerufen am: 26.02.2018].
 15. F. Hoffmann-La Roche. Primary Clinical Study Report – Protocol WA21093 – A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis – Report No. 1062035 – March 2016: OPERA II; 2016.
 16. ClinicalTrials.gov, Hoffmann-La Roche. A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis - ClinicalTrials.gov: OPERA II, NCT01412333, WA21093, 2010-020315-36; 2017. URL: <https://clinicaltrials.gov/ct2/show/record/NCT01412333> [aufgerufen am: 26.02.2018].
 17. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. *Lancet* 2011; 378(9805):1779–87.

Anhang 4-A: Suchstrategien – bibliografische Literaturrecherche

Datenbankname	EMBASE	
Suchoberfläche	Ovid	
Datum der Suche	08.12.2010	
Zeitsegment	1980 to 2010 week 50	
Suchfilter	Filter für randomisierte kontrollierte Studien nach Wong 2006 [Quelle ¹] – Strategy minimizing difference between sensitivity and specificity	
#	Suchbegriffe	Ergebnis
1	Meglitinide/	848
2	Nateglinide/	1686
3	Repaglinide/	2118
4	(glinid* or meglitinid* or nateglinid* or repaglinid*).ab,ti.	1069
5	(starlix or novonorm or novo norm or prandin).ab,ti.	32
6	(105816-04-4 or 135062-02-1).rn.	2854
7	or/1-6	3467
8	Diabetes mellitus/	224164
9	Non Insulin dependent Diabetes mellitus/	91081
10	(diabet* or niddm or t2dm).ab,ti.	379777
11	or/8-10	454517
12	(random* or double-blind*).tw.	650136
13	placebo*.mp.	243550
14	or/12-13	773621
15	and/7,11,14	719

¹ Das Zitat zu dem hier beispielhaft angegebenen Suchfilter lautet wie folgt: Wong SSL, Wilczynski NL, Haynes RB. Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. J Med Libr Assoc 2006; 94(4): 451-455. Hinweis: Für die Suche in der Cochrane-Datenbank „Cochrane Central Register of Controlled Trials (Clinical Trials)“ sollte kein Studienfilter verwendet werden.

Anhang 4-A1: Suche nach RCT mit dem zu bewertenden Arzneimittel

Datenbankname	MEDLINE	
Suchoberfläche	ProQuest Dialog	
Datum der Suche	14.02.2018	
Zeitsegment	Keine Einschränkung	
Suchfilter	Filter für randomisierte kontrollierte Studien nach Wong 2006 (1) – Strategy minimizing difference between sensitivity and specificity Angepasst für die ProQuest Syntax	
#	Suchbegriffe	Ergebnis
S1	all(ocrelizumab* or ocrevus*)	177
S2	all(rhumab p/0 2h7 or rhumab2h7)	1
S3	all("637334-45-3")	0
S4	all(A10SJL62JY)	58
S5	all(pro p/0 70769 or pro70769 or pr p/0 070769 or pr070769)	2
S6	all(r p/0 1594 or r1594 or rg1594 or rg p/0 1594 or ro4964913 or ro p/0 4964913 or ro p/0 496 p/0 4913)	100
S7	s1 or s2 or s3 or s4 or s5 or s6	279
S8	MESH.EXACT.EXPLODE("Multiple Sclerosis")	51778
S9	ti,ab(multiple p/0 scleros* or disseminated p/0 scleros* or RRMS or RMS or MS)	317425
S10	s8 or s9	323340
S11	rtype.exact("Randomized Controlled Trial")	453360
S12	ti,ab,su(randomized)	569343
S13	ti,ab,su(placebo)	206049
S14	s11 or s12 or s13	819072
S15	s7 and s10 and s14	19

Datenbankname	Embase	
Suchoberfläche	ProQuest Dialog	
Datum der Suche	14.02.2018	
Zeitsegment	Keine Einschränkung	
Suchfilter	Filter für randomisierte kontrollierte Studien nach Wong 2006 (1) – Strategy minimizing difference between sensitivity and specificity Angepasst für die ProQuest Syntax	
#	Suchbegriffe	Ergebnis
S1	all(ocrelizumab* or ocrevus*)	974
S2	EMB.EXACT("ocrelizumab")	956
S3	all(rhumab p/0 2h7 or rhumab2h7)	1
S4	all("637334-45-3")	825
S5	all(A10SJL62JY)	0
S6	all(pro p/0 70769 or pro70769 or pr p/0 070769 or pr070769)	20
S7	all(r p/0 1594 or r1594 or rg1594 or rg p/0 1594 or ro4964913 or ro p/0 4964913 or ro p/0 496 p/0 4913)	17
S8	s1 or s2 or s3 or s4 or s6 or s7	996
S9	EMB.EXACT.EXPLODE("multiple sclerosis")	117827
S10	ti,ab(multiple p/0 scleros* or disseminated p/0 scleros* or RRMS or RMS or MS)	433737
S11	s9 or s10	454252
S12	ti,ab(random*)	1275189
S13	ti,ab,su(placebo*)	414996
S14	ti,ab(double p/0 blind*)	189237
S15	s12 or s13 or s14	1524628
S16	s8 and s11 and s15	227

Datenbankname	The Cochrane Library	
Suchoberfläche	Cochrane (http://onlinelibrary.wiley.com/cochranelibrary/search/)	
Datum der Suche	14.02.2018	
Zeitsegment	Keine Einschränkung	
Suchfilter	Keiner verwendet	
#	Suchbegriffe	Ergebnis
#1	ocrelizumab* or ocrevus*	94
#2	rhumab-2h7 or "rhumab 2h7" or rhumab2h7	0
#3	pro-70769 or pro70769 or "pro 70769"	0
#4	pr-070769 or "pr 070769" or pr070769	0
#5	r1594 or r-1594 or "r 1594"	0
#6	rg1594 or rg-1594 or "rg 1594"	0
#7	ro4964913 or ro-4964913 or "ro 4964913" or ro-496-4913 or "ro 496 4913"	0
#8	637334-45-3 or A10S JL62JY	0
#9	MeSH descriptor: [Multiple Sclerosis] explode all trees	2431
#10	multiple scleros* or disseminated scleros* or RRMS or RMS or MS:ti,ab,kw (Word variations have been searched)	15620
#11	#9 or #10	15620
#12	#1 and #11	73*
* Davon aus CENTRAL		66

Anhang 4-B1: Suche nach RCT mit dem zu bewertenden Arzneimittel

Studienregister:	clinicaltrials.gov	
Internetadresse	https://clinicaltrials.gov/ct2/home	
Datum der Suche	14.02.2018	
Suchstrategie		
#	Suchbegriffe [Basic search]	Treffer
1	ocrelizumab OR ocrevus OR rhumab-2h7 OR rhumab 2h7 OR rhumab2h7 OR pro-70769 OR pro 70769 OR pro70769 OR pr-070769 OR pr 070769 OR pr070769 OR r 1594 OR ro-4964913 OR ro 4964913 OR ro4964913	30
Für den abschließenden Export wurden nur Synonyme und Schreibweisen miteinander kombiniert, zu denen es Treffer in der Datenbank gab. Zusätzlich wurden vorab folgende Begriffe getestet: r-1594, r1594, rg-1594, rg 1594, rg1594, ro-496-4913, ro 496 4913, 637334-45-3 (jeweils 0 Treffer).		

Studienregister:	ICTRP	
Internetadresse	http://apps.who.int/trialsearch/	
Datum der Suche	14.02.2018	
Suchstrategie		
#	Suchbegriffe [Basic search]	Treffer
1	ocrelizumab OR rhumab-2h7 OR rhumab 2h7 OR pro70769 OR r 1594 OR ro-496-4913 OR ro 496 4913 OR ro4964913 OR 637334-45-3	54
Für den abschließenden Export wurden nur Synonyme und Schreibweisen miteinander kombiniert, zu denen es Treffer in der Datenbank gab. Zusätzlich wurden vorab folgende Begriffe getestet: ocrevus, rhumab2h7, pro-70769, pro 70769, pr-070769, pr 070769, pr070769, r-1594, r1594, rg-1594, rg 1594, rg1594, ro-4964913, ro 4964913 (jeweils 0 Treffer).		

Studienregister:	EU clinical trials register	
Internetadresse	https://www.clinicaltrialsregister.eu/ctr-search/search	
Datum der Suche	14.02.2018	
Suchstrategie		
#	Suchbegriffe [Basic search]	Treffer
1	ocrelizumab OR "rhumab 2h7" OR pro70769 OR ro-496-4913 OR ro4964913 OR 637334-45-3	15
Für den abschließenden Export wurden nur Synonyme und Schreibweisen miteinander kombiniert, zu denen es Treffer in der Datenbank gab. Zusätzlich wurden vorab folgende Begriffe getestet: ocrevus, rhumab-2h7, rhumab2h7, pro-70769, "pro 70769", pr-070769, "pr 070769", pr070769, r-1594, "r 1594", r1594, rg-1594, "rg 1594", rg1594, "ro 496 4913", ro-4964913, "ro 4964913" (jeweils 0 Treffer).		

Studienregister:	PharmNet.Bund – Klinische Prüfungen		
Internetadresse	http://www.pharmnet-bund.de/dynamic/de/klinische-pruefungen/index.html		
Datum der Suche	14.02.2018		
Suchstrategie			
#	Suchbegriffe	Felder	Treffer
1	(FT=?ocrelizumab? OR (MEDPROD:MPCODE=?"ocrelizumab"? OR MEDPROD:MPNAME=?"ocrelizumab"? OR MEDPROD:MPMEM-STATETRNAM=?"ocrelizumab"?)) OR (ASUINN=?"ocrelizumab"? OR ASUSUPPCODE=?"ocrelizumab"? OR ASUODESCNAME=?"ocrelizumab"?)	[Textfelder] / [Product name/code] / [Active substance]	12
2	(FT=?rhumab 2h7? OR (MEDPROD:MPCODE=?"rhumab 2h7"? OR MEDPROD:MPNAME=?"rhumab 2h7"? OR MEDPROD:MPMEM-STATETRNAM=?"rhumab 2h7"?)) OR (ASUINN=?"rhumab 2h7"? OR ASUSUPPCODE=?"rhumab 2h7"? OR ASUODESCNAME=?"rhumab 2h7"?)	[Textfelder] / [Product name/code] / [Active substance]	5
3	(FT=?ro4964913? OR (MEDPROD:MPCODE=?"ro4964913"? OR MEDPROD:MPNAME=?"ro4964913"? OR MEDPROD:MPMEM-STATETRNAM=?"ro4964913"?)) OR (ASUINN=?"ro4964913"? OR ASUSUPPCODE=?"ro4964913"? OR ASUODESCNAME=?"ro4964913"?)	[Textfelder] / [Product name/code] / [Active substance]	7
4	ASUCASNR=?"637334-45-3"?	[CAS number]	7
Anzahl Treffer gesamt			12*
* Die Ergebnisse für jede einzelne der Strategien 1-4 wurden jeweils einzeln exportiert und anschließend um Duplikate bereinigt (Anzahl Treffer gesamt) Zusätzlich wurden folgende Begriffe getestet: ?Ocrevus?, ?rhumab-2h7?, ?rhumab2h7?, ?pro-70769?, ?pro 70769?, ?pro70769?, ?pr-070769?, ?pr 070769?, ?pr070769?, ?r-1594?, ?r 1594?, ?r1594?, ?rg-1594?, ?rg 1594?, ?rg1594?, ?ro-496-4913?, ?ro 496 4913?, ?ro-4964913?, ?ro 4964913?, jeweils in den Feldern „Textfelder“, „Product name/code“ oder „Active substance“ (jeweils 0 Treffer).			

Anhang 4-B: Liste der im Volltext gesichteten und ausgeschlossenen Dokumente mit Ausschlussgrund (bibliografische Literaturrecherche)**Anhang 4-C1: Suche nach RCT mit dem zu bewertenden Arzneimittel**

Autor	Jahr	Ausschlussgrund	Begründung	Quelle
Kappos <i>et al.</i>	2011	A6	Dauer RCT-Phase 24 Wochen	(17)

Anhang 4-C: Liste der ausgeschlossenen Studien mit Ausschlussgrund (Suche in Studienregistern)**Anhang 4-D1: Suche nach RCT mit dem zu bewertenden Arzneimittel**

Register	Trefferzahl (Anhang 4-B)	Ausgeschlossene Registereinträge	Eingeschlossene Registereinträge
ClinicalTrials.gov	30	28	2
ICTRP	54	50	4
EU-CTR	15	13	2
PharmNet.Bund	12	10	2
Summe	$\Sigma = 111$	$\Sigma = 101$	$\Sigma = 10$

#	Studiennummer	Zitat	Ausschlussgrund
Clinicaltrials.gov			
1	NCT00077870	Genentech Inc.; A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis; (NCT00077870, ACT2847g); [Last Updated: September 3, 2009].	A1
2	NCT00153101	Boehringer Ingelheim; Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo; (NCT00153101, 502.373); [Last Updated: May 20, 2014].	A1
3	NCT00406419	Genentech Inc., Roche Pharma AG; A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE); (NCT00406419, ACT3985g, WA20494); [Last Updated: May 15, 2017].	A1
4	NCT00476996	Genentech Inc., Roche Pharma AG; A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF- α Therapy (SCRIPT); (NCT00476996, ACT3986g, WA20495); [Last Updated: May 11, 2017].	A1
5	NCT00485589	Genentech Inc., Roche Pharma AG; A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM); (NCT00485589, ACT3984g, WA20497); [Last Updated: May 11, 2017].	A1
6	NCT00539838	Genentech Inc., Roche Pharma AG; A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN); (NCT00539838, ACT4071g, WA20499); [Last Updated: May 15, 2017].	A1
7	NCT00626197	Genentech Inc., Roche Pharma AG; A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BE-LONG); (NCT00626197, ACT4072g, WA20500); [Last Updated: May 10, 2017].	A1

8	NCT00673920	Genentech Inc., Roche Pharma AG; A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy; (NCT00673920, ACT4394g, WA20496); [Last Updated: May 11, 2017].	A1
9	NCT00676715	Genentech Inc., Roche Pharma AG; A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis; (NCT00676715, ACT4422g, 2007-006338-32, WA21493); [Last Updated: January 25, 2018].	A6
10	NCT00779220	Chugai Pharmaceutical; A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis; (NCT00779220, JA21963); [Last Updated: March 25, 2015].	A1
11	NCT00808210	Genentech Inc.; A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab; (NCT00808210, ACT4562g, GA00931); [Last Updated: November 2, 2016].	A1
12	NCT01194570	Hoffmann-La Roche; A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis; (NCT01194570, WA25046, 2010-020338-25); [Last Updated: December 26, 2017].	A1
13	NCT01299883	University of Pennsylvania; West Philadelphia Consortium Randomized Control Trial; (NCT01299883, 5R24MDOO1594-06); [Last Updated: October 11, 2017].	A1
14	NCT01765361	University Hospital Basel Switzerland; Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG); (NCT01765361, EP-OCR); [Last Updated: February 1, 2017].	A7
15	NCT02545868	Hoffmann-La Roche; A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis; (NCT02545868, BN29739, 2015-001357-32); [Last Updated: December 14, 2017].	A3
16	NCT02637856	Genentech Inc.; A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT); (NCT02637856, MN30035); [Last Updated: December 19, 2017].	A3
17	NCT02688985	Genentech Inc.; Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS); (NCT02688985, ML29966, 2015-004616-37); [Last Updated: January 24, 2018].	A3
18	NCT02720120	Hoffmann-La Roche; A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA); (NCT02720120, WA18230, 2004-002132-26); [Last Updated: March 28, 2016].	A1
19	NCT02723071	Hoffmann-La Roche; A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL); (NCT02723071, BO18414, 2004-004110-17); [Last Updated: March 30, 2016].	A1
20	NCT02807285	Genentech Inc.; Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis; (NCT02807285, ML29972); [Last Updated: September 7, 2017].	A1
21	NCT02861014	Hoffmann-La Roche; A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT); (NCT02861014, MA30005, 2015-005597-38); [Last Updated: December 29, 2017].	A3
22	NCT02980042	University of Colorado Denver; Tolerability and Safety of Switching From Rituximab to Ocrelizumab in Patients With Relapsing Forms of	A3

		Multiple Sclerosis; (NCT02980042, 16-1354); [Last Updated: December 26, 2017].	
23	NCT03025269	University at Buffalo; Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis; (NCT03025269, STUDY00001202); [Last Updated: December 5, 2017].	A3
24	NCT03085810	Hoffmann-La Roche; Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS); (NCT03085810, MA30143, 2016-002937-31); [Last Updated: February 5, 2018].	A3
25	NCT03138525	Brigham and Women's Hospital, Genentech Inc.; Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis; (NCT03138525, ML39789); [Last Updated: July 14, 2017].	A3
26	NCT03157830	Providence Health & Services, Genentech Inc.; Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab; (NCT03157830, Study2017000156); [Last Updated: June 14, 2017].	A3
27	NCT03344094	University of Chicago; Mechanism of Action of Ocrelizumab in Multiple Sclerosis; (NCT03344094, IRB10681A); [Last Updated: November 17, 2017].	A5
28	NCT03396822	University of Maryland, Genentech Inc.; Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis; (NCT03396822, HP-00074320); [Last Updated: January 12, 2018].	A5
WHO ICTRP			
29	EUCTR2004-001594-25-FI	Merck KGaA; A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2; (EUCTR2004-001594-25-FI, EMR62225-019); [Last Updated: 19 March 2012].	A1
30	EUCTR2004-002132-26-GB	F. Hoffmann-La Roche Limited; A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMab 2H7) in patients with moderate to severe rheumatoid arthritis receiving stable doses of concomitant methotrexate but with unsatisfactory clinical response. - N/A; (EUCTR2004-002132-26-GB, WA18230); [Last Updated: 2 October 2012].	A1
31	EUCTR2004-004110-17-SE	Roche Products Limited; Full title of the trial : An open-label, multicentre, dose-escalating phase I/II trial of 3-weekly rhuMab 2H7 in patients with follicular non Hodgkin's lymphoma - N/A; (EUCTR2004-004110-17-SE, BO18414;N/A); [Last Updated: 19 March 2012].	A1
32	EUCTR2006-005147-28-DE	F. Hoffmann-La Roche Ltd; A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment.; (EUCTR2006-005147-28-DE, WA20494); [Last Updated: 23 May 2016].	A1
33	EUCTR2006-005330-20-BE	F. Hoffmann-La Roche Ltd; A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-a therapy. -; (EUCTR2006-005330-20-BE, WA20495); [Last Updated: 25 September 2012].	A1
34	EUCTR2006-005353-30-ES	F. Hoffmann-La Roche Ltd; Estudio internacional, randomizado, doble ciego, con grupos de tratamiento paralelos para evaluar la seguridad y eficacia de ocrelizumab en combinación con metotrexato (MTX) comparado con MTX como único tratamiento, en pacientes con artritis reumatoide activa no tratados previamente con metotrexato; (EUCTR2006-005353-30-ES, WA20497); [Last Updated: 28 August 2014].	A1
35	EUCTR2006-005355-16-GB	F. Hoffmann-La Roche Ltd; A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy	A1

		and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus; (EUCTR2006-005355-16-GB, WA20499); [Last Updated: 19 March 2012].	
36	EUCTR2006-005357-29-GB	F. Hoffmann-La Roche Ltd; A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephritis Due To Systemic Lupus Erythematosus; (EUCTR2006-005357-29-GB, WA20500); [Last Updated: 3 April 2012].	A1
37	EUCTR2007-005759-41-FR	F. Hoffmann-La Roche Ltd; A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with Active Rheumatoid Arthritis Who Have an inadequate Response to Methotrexate Therapy; (EUCTR2007-005759-41-FR, WA20496); [Last Updated: 19 March 2012].	A1
38	EUCTR2007-006338-32-FR	Hoffman La Roche Ltd; Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis; (EUCTR2007-006338-32-FR, WA21493); [Last Updated: 18 September 2012].	A6
39	EUCTR2012-001594-93-FR	Innate Pharma; Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly patients with Acute Myeloid Leukemia (AML) in First Complete Remission; (EUCTR2012-001594-93-FR, IPH2102-201); [Last Updated: 6 February 2017].	A1
40	EUCTR2014-001594-14-DE	Universitätsklinikum Erlangen; Prospective, single-centre, open-label, one-arm clinical trial, phase I/IIa, to assess the safety and tolerability and to investigate the predictive power of FITC-Adalimumab, when topically applied twice to the intestinal mucosa as an in-vitro diagnostic in the framework of a confocal laser-endomicroscopic examination of colitis ulcerosa patients with an indication for Adalimumab treatment - MAGIC; (EUCTR2014-001594-14-DE, FITC-ADA-CU-01); [Last Updated: 8 January 2018].	A1
41	EUCTR2015-005597-38-GB	F. Hoffmann-La Roche Ltd; An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment - CASTING; (EUCTR2015-005597-38-GB, MA30005); [Last Updated: 6 November 2017].	A3
42	IS-RCTN82062639	University of Leicester; SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A randomised double-blind placebo-controlled trial (SEESAW); (ISRCTN82062639, 2015-001594-40, NCT02798744, 30653); [Last Updated: 5 February 2018].	A1
43	JPRN-JapicCTI-070479	Chugai Pharmaceutical Co., Ltd.; A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy.; (JPRN-JapicCTI-070479, NCT00476996); [Last Updated: 29 January 2018].	A1
44	JPRN-JapicCTI-080650	Chugai Pharmaceutical Co., Ltd.; Dose-Response Study of Ocrelizumab for Rheumatoid Arthritis.; (JPRN-JapicCTI-080650); [Last Updated: 29 January 2018].	A1
45	JPRN-JapicCTI-090764	Chugai Pharmaceutical Co., Ltd.; Long-Term Treatment Study of Ocrelizumab for Rheumatoid Arthritis; (JPRN-JapicCTI-090764); [Last Updated: 29 January 2018].	A1
46	NCT00004103	New York University School of Medicine, National Cancer Institute (NCI); A Phase II Study of Systemic Therapy With CPT-11 (Camptosar HCl) and Cisplatin in Patients With Advanced Gastric Cancer to be Followed by Surgical Resection and Postoperative Intraperitoneal Chemotherapy; (NCT00004103, P30CA016087, NYU-9822, P-UPJOHN-	A1

		647597196, NCI-G99-1594, CDR0000067322); [Last Updated: 19 February 2015].	
47	NCT00005958	Amgen; Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim; (NCT00005958, AMGEN-GCSF-990125, NCI-V00-1594, CDR0000067939); [Last Updated: 19 February 2015].	A1
48	NCT00077870	Genentech, Inc.; A Randomized, Placebo-Controlled, Multicenter, Blinded Phase I/II Study of the Safety of Escalating Doses of Ocrelizumab (PRO70769) in Subjects With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate; (NCT00077870, ACT2847g); [Last Updated: 19 February 2015].	A1
49	NCT00104858	Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI); Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial; (NCT00104858, NCI-2009-01594, 1840.00, P01CA018029, P30CA015704, 1840.00); [Last Updated: 16 December 2017].	A1
50	NCT00184626	Novo Nordisk A/S; Safety and Efficacy of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.; (NCT00184626, BIASP-1594); [Last Updated: 16 December 2017].	A1
51	NCT00406419	Genentech, Inc., Roche Pharma AG; A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment; (NCT00406419, WA20494, ACT3985g); [Last Updated: 16 December 2017].	A1
52	NCT00476996	Genentech, Inc., Roche Pharma AG; A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-a Therapy; (NCT00476996, WA20495, ACT3986g); [Last Updated: 16 December 2017].	A1
53	NCT00525720	M.D. Anderson Cancer Center; Transperineal Interstitial Permanent Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma; (NCT00525720, NCI-2012-01594, 2006-0038); [Last Updated: 16 December 2017].	A1
54	NCT00539838	Genentech, Inc., Roche Pharma AG; A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus; (NCT00539838, WA20499, ACT4071g); [Last Updated: 16 December 2017].	A1
55	NCT00626197	Genentech, Inc., Roche Pharma AG; A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus; (NCT00626197, WA20500, ACT4072g); [Last Updated: 16 December 2017].	A1
56	NCT00673920	Genentech, Inc., Roche Pharma AG; A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy; (NCT00673920, WA20496, ACT4394g); [Last Updated: 16 December 2017].	A1
57	NCT00676715	Genentech, Inc., Roche Pharma AG; Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS; (NCT00676715, 2007-006338-32, WA21493, ACT4422g); [Last Updated: 5 February 2018].	A6

58	NCT00779220	Chugai Pharmaceutical; A Randomized, Double-blind, Parallel-group, Study to Evaluate the Efficacy, Safety and PK/PD of Ocrelizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy; (NCT00779220, JA21963); [Last Updated: 7 April 2015].	A1
59	NCT00808210	Genentech, Inc.; A PHASE II RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMBINATION WITH METHOTREXATE, COMPARED TO INFlixIMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS CURRENTLY RESPONDING INADEQUATELY TO ETANERCEPT OR ADALIMUMAB; (NCT00808210, GA00931, ACT4562g); [Last Updated: 14 November 2016].	A1
60	NCT01194570	Hoffmann-La Roche; A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis; (NCT01194570, 2010-020338-25, WA25046); [Last Updated: 8 January 2018].	A1
61	NCT01765361	University Hospital, Basel, Switzerland; Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG); (NCT01765361, EP-OCR); [Last Updated: 16 December 2017].	A7
62	NCT02138955	SignPath Pharma, Inc.; A PHASE Ib DOSE ESCALATION STUDY ON THE SAFETY, TOLERABILITY AND ACTIVITY OF LIPOSOMAL CURCUMIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER; (NCT02138955, 0011594-24, SPP1002, 2013-001594-24, Lipocurc1002/P-1-010); [Last Updated: 16 December 2017].	A1
63	NCT02252978	Wake Forest University Health Sciences, National Cancer Institute (NCI); A Phase II, Double-Blind, Placebo-Controlled Prospective Randomized Clinical Trial Evaluating the Role of an Empiric 2-Week Course of Ciprofloxacin on Rates of Detection of Cancer by Prostate Biopsy in Men With Abnormal Serum Prostate Specific Antigen Found at Screening (PREP Trial); (NCT02252978, NCI-2014-01594, CCCWFU 99712, P30CA012197, CCCWFU 99712); [Last Updated: 16 December 2017].	A1
64	NCT02545868	Hoffmann-La Roche; A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis; (NCT02545868, 2015-001357-32, BN29739); [Last Updated: 8 January 2018].	A3
65	NCT02637856	Genentech, Inc.; An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment; (NCT02637856, MN30035); [Last Updated: 8 January 2018].	A3
66	NCT02688985	Genentech, Inc.; An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis; (NCT02688985, 2015-004616-37, ML29966); [Last Updated: 5 February 2018].	A3
67	NCT02807285	Genentech, Inc.; An Open Label, MultiCenter, Expanded-Access Program for Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis; (NCT02807285, ML29972); [Last Updated: 16 December 2017].	A1
68	NCT02816658	The Cleveland Clinic; The Role of the Robotic Platform in Inguinal Hernia Repair Surgery; (NCT02816658, 15-1594); [Last Updated: 16 December 2017].	A1

69	NCT02980042	University of Colorado, Denver; Evaluating the Tolerability and Safety Profile of Switching From Rituximab to Ocrelizumab: A Real World Evaluation of Patients With Relapsing Forms of Multiple Sclerosis; (NCT02980042, 16-1354); [Last Updated: 8 January 2018].	A3
70	NCT03025269	University at Buffalo; Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis; (NCT03025269, STUDY00001202); [Last Updated: 16 December 2017].	A3
71	NCT03085810	Hoffmann-La Roche; An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis; (NCT03085810, 2016-002937-31, MA30143); [Last Updated: 22 January 2018].	A3
72	NCT03092271	University of California, Los Angeles Kaiser Foundation Research Institute, University of Washington; Randomized Trial of Stepped Care for Suicide Prevention in Teens and Young Adults; (NCT03092271, 16-001594, 112147); [Last Updated: 16 December 2017].	A1
73	NCT03095781	Emory University, Merck Sharp & Dohme Corp., Exelixis Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies; (NCT03095781, NCI-2016-01594, Winship3321-16, IRB00087397); [Last Updated: 16 December 2017].	A1
74	NCT03138525	Brigham and Women's Hospital, Genentech, Inc.; Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis; (NCT03138525, ML39789); [Last Updated: 16 December 2017].	A3
75	NCT03157830	Providence Health & Services, Genentech, Inc. ; Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab.; (NCT03157830, Study2017000156); [Last Updated: 16 December 2017].	A3
76	NCT03344094	University of Chicago; Mechanism of Action of Ocrelizumab in Multiple Sclerosis; (NCT03344094, IRB10681A); [Last Updated: 16 December 2017].	A5
77	NCT03396822	University of Maryland, Genentech, Inc.; Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis; (NCT03396822, HP-00074320); [Last Updated: 22 January 2018].	A5
78	PER-098-10	F. HOFFMANN-LA ROCHE LTD.; A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; (PER-098-10, WA25046); [Last Updated: 30 January 2018].	A1
EU-CTR			
79	2004-002132-26	F. Hoffmann-La Roche Limited; A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMab 2H7) in patients with moder; (2004-002132-26, WA18230).	A1
80	2004-004110-17	Roche Products Limited; Full title of the trial : An open-label, multicentre, dose-escalating phase I/II trial of 3-weekly rhuMab 2H7 in patients with follicular non Hodgkin's lymphoma; (2004-004110-17, BO18414).	A1
81	2006-005147-28	F. Hoffmann-La Roche Ltd; A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing method; (2006-005147-28, WA20494).	A1
82	2006-005330-20	F. Hoffmann-La Roche Ltd; A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an in; (2006-005330-20, WA20495).	A1
83	2006-005353-30	F. Hoffmann-La Roche Ltd; Estudio internacional, randomizado, doble ciego, con grupos de tratamiento paralelos para evaluar la seguridad y	A1

		eficacia de ocrelizumab en combinación con metotrexato (MTX) comparado con MTX como; (2006-005353-30, WA20497).	
84	2006-005355-16	F. Hoffmann-La Roche Ltd; A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus; (2006-005355-16, WA20499).	A1
85	2006-005357-29	F. Hoffmann-La Roche Ltd; A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephrit; (2006-005357-29, WA20500).	A1
86	2007-005759-41	F. Hoffmann-La Roche Ltd; A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with; (2007-005759-41, WA20496).	A1
87	2007-006338-32	Hoffman La Roche Ltd; Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do; (2007-006338-32, WA21493).	A6
88	2010-020338-25	F.Hoffmann-La Roche; A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis; (2010-020338-25, WA25046).	A1
89	2015-004616-37	GENENTECH Inc.; An open-label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B-cell biology in patients with relapsing multiple sclerosis; (2015-004616-37, ML29966).	A3
90	2015-005597-38	F. Hoffmann-La Roche Ltd; An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modify; (2015-005597-38, MA30005).	A3
91	2016-002937-31	F. Hoffmann-La Roche Ltd; An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis; (2016-002937-31, MA30143).	A3
PharmNet.Bund			
92	2006-005147-28	F. Hoffmann-La Roche Ltd; A randomized, double blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment; (2006-005147-28).	A1
93	2006-005330-20	F. Hoffmann-La Roche Ltd; A randomized, double blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti TNF alpha therapy; (2006-005330-20).	A1
94	2006-005355-16	F. Hoffmann-La Roche Ltd; A Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus; (2006-005355-16).	A1
95	2006-005357-29	F. Hoffmann-La Roche Ltd; A Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephritis Due To Systemic Lupus Erythematosus; (2006-005357-29).	A1
96	2007-005759-41	F. Hoffmann-La Roche Ltd; A Randomized, Double Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy; (2007-005759-41).	A1
97	2007-006338-32	F. Hoffman-La Roche Ltd; Phase II, multicenter, randomized, parallel group, partially blinded, placebo and Avonex controlled dose finding	A6

		study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing remitting multiple sclerosis; (2007-006338-32).	
98	2010-020338-25	F.Hoffmann-La Roche; A Phase III, multicenter, randomized, parallel group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis; (2010-020338-25).	A1
99	2015-004616-37	GENENTECH Inc.; An open label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B cell biology in patients with relapsing multiple sclerosis or primary progressive multiple sclerosis; (2015-004616-37).	A3
100	2015-005597-38	F. Hoffmann-La Roche Ltd; An open label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease modifying treatment; (2015-005597-38).	A3
101	2016-002937-31	F. Hoffmann-La Roche Ltd; An Open Label, single arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis; (2016-002937-31).	A3